Home > Urology > EAU 2020 > Prostate Cancer & Imaging > Large patient-driven survey reveals QoL issues after prostate cancer treatment

Large patient-driven survey reveals QoL issues after prostate cancer treatment

Presented by
Mr André Deschamps , Europa Uomo, Belgium
EAU 2020
Findings from the EUPROMS study were reported by Mr André Deschamps (Chairman of Europa Uomo, Belgium) [1]. This study represents the first patient-driven quality-of-life (QoL) data collection and revealed specific long-term complaints correlating with a given treatment.

Europa Uomo is an umbrella organisation of European prostate cancer patient groups, which practices evidence-based patient advocacy and is active in EAU policy making regarding patient representation. When evidence of patient experience is lacking, organisations like Europa Uomo fill a critical gap in generating independent patient-reported outcomes.

In this case, the EUPROMS patient-driven QoL study included data from 2,943 men treated for prostate cancer from 24 countries (mean age 70 years at survey, mean age 64 years at diagnosis). Participants were asked to complete a 20-minute online survey to assay QoL of patients with or who had been treated for prostate cancer. The study used validated QoL questionnaires (i.e. EPIC-26, EORTC-QLQ-C30, and EQ-5D-5L) available in 19 languages. Of the respondents, two-third received 1 treatment for prostate cancer, 22% received 2 treatments, 19% received 3, and 2% received 4 or more.

Fatigue and insomnia were the most frequently reported complaints impacting QoL among participants. The data revealed that half of all respondents scored loss of sexual function (including the ability to have an erection or reach orgasm) as a “big” (28%) or “moderate” (22%) problem. Notably, the adverse impact of radiotherapy on sexual function was worse than that of radical prostatectomy. Alternatively, patients who underwent radical prostatectomy reported increased urinary incontinence compared with those undergoing radiation therapy. Radiation therapy doubled the reported fatigue compared with radical prostatectomy. Chemotherapy also led to an increase in reported fatigue. Insomnia appeared to be a function of progression of disease rather than the treatment received, except for chemotherapy, which did cause a marked increase in reported insomnia. Active surveillance had no impact on insomnia. As anticipated, chemotherapy resulted in the worst QoL outcomes.

Mr Deschamps concluded: “The data collected and the analysis done provide patients and healthcare professionals a snapshot on the impact of treatments based on the experiences of fellow patients. We hope that these results will be used to establish and disseminate realistic expectations on the effects of the different treatments for prostate cancer on QoL.”

Discussant Prof. Steven Joniau (University Hospital Leuven, Belgium) complimented the strengths of this study as being the large sample size, assessment at long-term follow-up (mean 6 years post diagnosis), and the use of validated questionnaire instruments. Weaknesses include the cross-sectional design, lack of a baseline assessment, and observational design. He continued to point out that because younger and healthier patients more likely underwent surgery and older, less healthy patients likely received radiation therapy, better insight into the baseline patient characteristics would help tease out relevant hypothesis-generating observations.

    1. Deschamps A, et al. EAU20 Virtual Congress, 17-26 July 2020. Game-changing Session 3.

Posted on